Nanoparticle formulation of ormeloxifene for pancreatic cancer.

2015 Jun;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.

Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects. Ormeloxifene (ORM), a synthetic molecule...

http://www.ncbi.nlm.nih.gov/pubmed/25890768